Opportunities for the treatment of inflammation in cardiovascular disease

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 11, 2001, Pages 1751-1763

  Crossman, D C ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Aspirin; Atherosclerosis; CD40; Inflammation; Myocardial infarction; Peroxisome proliferator activated receptor; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PRAVASTATIN; SALICYLIC ACID DERIVATIVE; SIMVASTATIN; STATINE DERIVATIVE;

AGONIST; ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE MARKER; DRUG EFFECT; DRUG MECHANISM; EPIDEMIOLOGY; HUMAN; MOUSE; NONHUMAN; PATHOGENESIS; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD40; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; LIPID PEROXIDATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 0035171244     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.11.1751     Document Type: Review

References (96)

1. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis
2. Medical progress. The pathogenesis of atherosclerosis - An update
3. The pathogenesis of atherosclerosis: A perspective for the 1990s
4. Atherosclerosis - An inflammatory disease
5. Atherosclerosis: The road ahead
6. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
7. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
8. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
9. Vitamin E supplementation and cardiovascular events in high-risk patients
10. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice
11. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice
12. Effect of chronic treatment with the inducible nitric oxide synthase inhibitor N-iminoethyl-L-lysine or with L-arginine on progression of coronary and aortic atherosclerosis in hypercholesterolemic rabbits
13. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E
14. Role of macrophage colony-stimulating factor in atherosclerosis: Studies of osteopetrotic mice
15. The combined role of P- and E-selectins in atherosclerosis
16. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E- deficient mice
17. ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE(-/-)/ICAM-1(-/-)) fed a fat or a chow diet
18. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis
19. T-cell function and migration. Two sides of the same coin
20. Chemokines, leukocytes, and atherosclerosis
21. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice
22. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B
23. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis
24. Enhanced production of the chemotactic cytokines interleukin-8 and monocyte chemoattractant protein-1 in human abdominal aortic aneurysms
25. IL-8 is an angiogenic factor in human coronary atherectomy tissue
26. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor- deficient mice
27. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
28. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
29. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma
30. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
31. PPARgamma agonists inhibit production of monocyte inflammatory cytokines
32. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through mononuclear phagocytes in vitro
33. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice
34. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
35. Immune mechanisms in atherosclerosis
36. An immunohistochemical analysis of human aortic fatty streaks
37. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1
38. Polyclonal origin of T lymphocytes in human atherosclerotic plaques
39. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse
40. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice
41. Cell-mediated immunity in atherosclerosis
42. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: A role for CD40 signaling in plaque rupture?
43. Expression of stromelysin-3 in atherosclerotic lesions: Regulation via CD40-CD40 ligand signaling in vitro and in vivo
44. Interleukin- 1 beta in coronary arteries of patients with ischemic heart disease
45. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein
46. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice
47. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice
48. Interleukin-10 blocks atherosclerotic events in vitro and in vivo
49. Protective role of interleukin-10 in atherosclerosis
50. CD40-CD40 ligand
51. CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression
52. Functional interactions of T cells with endothelial cells: The role of CD40L-CD40-mediated signals
53. Expression of functional CD40 by vascular endothelial cells
54. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40
55. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression
56. Ligation of CD40 activates interleukin 1 beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1 beta
57. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
58. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells
59. Reduction of atherosclerosis in mice by inhibition of CD40 signalling
60. Requirement for CD154 in the progression of atherosclerosis
61. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
62. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death
63. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly
64. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death
65. Factors influencing the presence or absence of acute coronary-artery thrombi in sudden ischemic death
66. Multiple complex coronary plaques in patients with acute myocardial infarction
67. Coronary plaque disruption
68. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques
69. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
70. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
71. C Reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study
72. Hemostatic factors and the risk of myocardial-infarction or sudden-death in patients with angina-pectoris
73. Production of C-reactive protein and risk of Coronary events in stable and unstable angina
74. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly - Results from the Cardiovascular Health Study and the Rural Health Promotion Project
75. The prognostic value of c-reactive protein and seum amyloid-a protein in severe unstable angina
76. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease
77. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function
78. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
79. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. Fragmin during Instability in Coronary Artery Disease
80. C-Reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
81. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study
82. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
83. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events
84. Perturbation of the T-cell repertoire in patients with unstable angina
85. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries
86. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction
87. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKbeta
88. Long-term effects of pravastatin on plasma concentration of C-reactive protein
89. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
90. New evidence for beneficial effects of statins unrelated to lipid lowering
91. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering
92. Statins as a newly recognized type of immunomodulator
93. Effect of pravastatin on outcomes after cardiac transplantation
94. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial
95. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection
96. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice